Protandim and The Ohio State Study on Heart Disease
Protandim and The Ohio State Study on Heart Disease
Elite Academy 5, January 21, 2011
This is a training session for Protandim Distributors, where Dr. McCord explains the “Ohio State” Study conducted over a period of 4 years between 2006 to 2010. This study was published by Free Radical Biology & Medicine, an international interdisciplinary journal that publishes peer-reviewed contributions and reviews. It is entitled, “Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway.”
The abstract of the study notes that human saphenous veins (HSVs) are widely used for bypass grafts. Among the purposes of the study was “to explore the potential therapeutic effects of up-regulating endogenous antioxident enzymes. Protandim is a nutritional supplement “known to activate Nrf2 and increase the expression of antioxidant enzymes.”
In short, this study examined Protandim’s potential influence in the treatment of cardiovascular disease. The outcome of the study, conducted by Ohio State University, was that Protandim has been found to prevent a process that causes blood vessel blockage. Protandim prevents the proliferation of cells that can cause re-blockage of blood vessels following coronary artery surgery. This study, as well as other recent studies, have shown that Protandim® provides benefits to the body that extend beyond its ability to decrease oxidative stress. The article can be found on PubMed.
In this video presentation Dr. McCord explains how Protandim acts as a Nrf2 activator, which in layman’s terms means that Protandim is “a biochemical wake up call to every cell in your body.” It interacts with an enzyme known as Nrf2, which has been identified as “the master regulator of survival genes” in the DNA of our cells. Dr. McCord calls DNA the “central blueprint that controls everything that you are and everything that your body can produce.” These “survival genes” are stress-response genes, some producing antioxident enzymes. While intitally thought to regulate two specific enzymes, Protandim is now known to up-regulate at least 400, and perhaps as many as 800 enzymes. Dr. McCord also refers to an older study, conducted in 2004, which concluded that serum levels of “thiobarbituric acid reactive substances,” aka TBARS, are more strongly predictive of cardiovascular events than traditional risk factors and inflammatory markers. The higher the measure of TBARS, the greater the likelihood that a cardiovascular event, such as an attack of angina, chest pains upon exertion, a myocardial infarction (heart attack), will occur. Protandim has been shown effective in reducing TBARS levels.
Dr. McCord discusses how oxidative stress is hypothesized to give rise to atherosclerosis or hardening of the arteries, and plaque formation that ultimately clogs arteries. LDL cholesterol is important for the body, but should be kept at low levels. It is believed that oxidized LDL leads to atherosclerosis. Because of Protandim’s known effectiveness in helping the body produce antioxidants, it stands to reason that Protandim may help prevent atherosclerosis. This was the point of the Ohio State study.
Oxidative stress leads to intimal hyperplasia, which is a thickening of the walls of the blood vessels, a phenomenon studied by Ohio State University. Dr. McCord explains that artery walls are comprised of thee distinct layers. The intimal layer of the artery wall is the innermost layer, which was a focus in the Ohio State study. The next layer is the medial, and the outer layer surrounding the blood vessel is the adventitial layer.
The Ohio State study demonstrated that Protandim prevents wall thickening (intimal hyperplasia) in blood vessels, and does so by increasing antioxidant enzymes in blood vessels. HO-1 was shown to increase 700%, SOD by 250% and the key enzyme Catalase increased by 1200%.
The Ohio State study concluded that saphenous veins used in arterial bypass surgery suffer from oxidative stress due to the higher concentration of oxygen in arterial blood. A consequence of the increased oxidative stress is intimal hyperplasia, a thickening of the vessel wall, which can eventually reduce blood flow and lead to re-blockage, or restenosis, of the vessel.
The Ohio State study shows that Protandim prevented intimal hyperplasia in saphenous veins cultured ex vivo at arterial oxygen concentrations, suggesting that Nrf2 activation may extend the life of arterialized vein grafts in vivo.
Intimal hyperplasia leads to late failure (from 3 months to 10 years) following three common vascular surgeries: Coronary artery bypass graft surgery (CABG), Angioplasty, with or without stent insertion, and Carotid artery endarterectomy. Together these three procedures put about 1.5 million Americans per year at risk for complications due to intimal hyperplasia.
If Protandim can have an important impact on lessening these risks in post surgery patients, think what it might do to prevent the coronary artery disease in the first place. We cannot make such claims, of course, but it does seem to make perfect sense when you understand the nature of such disease, and what Protandim apparently does for the body.
Playing time: 45 minutes.